Clinical Trials on Chronic Obstructive Pulmonary Disease Severe in Colombia

Total 1991 results

Sunovion

Completed

A Dose Ranging Study of Arformoterol Given Once Daily Compared to Arformoterol Given Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

COPD

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States
Novartis

Completed

12-week Efficacy of Indacaterol

Chronic Obstructive Pulmonary Disease

United States
Novartis Pharmaceuticals

Completed

Long Term Safety Study of NVA237 vs QAB149 in COPD Patients

Chronic Obstructive Pulmonary Disease (COPD)

United States
Laval University
Takeda; Innovair

Terminated

Impact of Roflumilast on Visceral Adiposity and Metabolic Profile in Chronic Obstructive Pulmonary Disease (RAMBO)

Chronic Obstructive Pulmonary Disease | Metabolic Syndrome

Canada
AstraZeneca

Completed

A Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at Three Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Tiotropium

Chronic Obstructive Pulmonary Disease

Korea, Republic of, Poland, Germany, Philippines, Ukraine, Japan, United States, Australia, Canada, Slovakia, Taiwan, Russian Federation
AstraZeneca

Completed

Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Austria, Bulgaria, Canada, Czech Republic, France, Germany, Hungary, Italy, Lithuania, Netherlands, Poland, South Africa, Spain, United Kingdom
Novartis

Completed

Efficacy, Safety, and Tolerability of Once Daily Indacaterol in Chronic Obstructive Pulmonary Disease (COPD) Using Formoterol Twice Daily as Active Control

Chronic Obstructive Pulmonary Disease

Russian Federation, United Kingdom, Spain, Germany, Argentina, Italy, Netherlands, Switzerland, Turkey, France, Czech Republic, Hungary, Slovakia, Peru, Korea, Republic of, Colombia, Israel, Chile, Denmark, Ecuador, Egypt, Estonia, ... and more
AstraZeneca

Completed

AMPLIFY - D6571C00001 Duaklir USA Phase III Study

Chronic Obstructive Pulmonary Disease

United States, Germany, Poland, Israel, Bulgaria, Czechia, Hungary, Spain, Ukraine, United Kingdom
Hoffmann-La Roche

Recruiting

A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (ARNASA)

Chronic Obstructive Pulmonary Disease (COPD)

United States, China, Spain, Italy, Belgium, Korea, Republic of, Poland, Taiwan, Israel, United Kingdom, Japan, Czechia, New Zealand, Philippines, Hong Kong, Greece, Australia, Thailand, Netherlands, Argentina, France, India, Canada, ... and more
Novartis

Completed

1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD) (GLOW2)

Chronic Obstructive Pulmonary Disease

United States, Argentina, Germany, Russian Federation, France, Israel, Korea, Republic of, Italy, Poland, Chile, Mexico, Peru, Canada, Hungary, Netherlands, New Zealand
AstraZeneca

Completed

Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38) (LAS-MD-38)

Chronic Obstructive Pulmonary Disease

United States, Canada
Novartis Pharmaceuticals

Completed

A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (SHINE)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Russian Federation, Taiwan, Canada, Germany, Philippines, South Africa, Spain, United Kingdom, Turkey, Hungary, Guatemala, Australia, Bulgaria, France, Poland, Switzerland, Slovakia, Japan
Simon Fraser University
Canadian Institutes of Health Research (CIHR); Michael Smith Foundation for...

Completed

Trial of an Internet-based Platform for Managing Chronic Diseases at a Distance (iCDM)

Heart Failure | Diabetes | Chronic Obstructive Pulmonary Disease | Chronic Kidney Disease | Ischemic Heart Disease

Canada
Novartis Pharmaceuticals

Completed

A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.

Chronic Obstructive Pulmonary Disease (COPD)

United States, Poland, Romania, Canada, Philippines, Spain, Ukraine, Vietnam
Novartis Pharmaceuticals

Completed

Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations (SPARK)

Chronic Obstructive Pulmonary Disease

Germany, United States, Colombia, Poland, South Africa, Canada, Estonia, Hungary, India, Austria, Israel, Netherlands, United Kingdom, Argentina, France, Italy, Spain, Czech Republic, Denmark, Finland, Greece, Ireland, Mexico, Peru, Phi... and more
Sanofi
Regeneron Pharmaceuticals

Recruiting

A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD (AERIFY-4)

Chronic Obstructive Pulmonary Disease

United States, Argentina, Bulgaria, Chile, China, Czechia, Hungary, Israel, Poland, Taiwan, Canada, Portugal, United Kingdom, Korea, Republic of, Japan, Slovakia, South Africa
Verona Pharma plc
Iqvia Pty Ltd

Completed

A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD

Chronic Obstructive Pulmonary Disease

Denmark, United States, Bulgaria, Belgium, Poland, Spain, Canada, Estonia, Hungary, Slovakia
Theravance Biopharma
Viatris Inc.

Completed

Phase 4 COPD and Suboptimal Inspiratory Flow Rate (PIFR-2)

Chronic Obstructive Pulmonary Disease

United States
Novartis Pharmaceuticals

Completed

A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD) (INTENSITY)

Chronic Obstructive Pulmonary Disease

United States, Spain, Switzerland, France, Italy, Germany, Turkey, Hungary, Norway, Slovakia, Poland, Russian Federation, Canada, Belgium, Austria, Colombia, Denmark, Finland, Greece, Israel, Mexico, United Kingdom
AstraZeneca

Active, not recruiting

Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations (RESOLUTE)

Chronic Obstructive Pulmonary Disease

United States, Austria, Canada, Denmark, Germany, Italy, Spain, United Kingdom, Belgium, Vietnam, Brazil, Hungary, Philippines, China, Korea, Republic of, Argentina, Australia, Poland, Turkey, Japan, Greece, Netherlands, Czechia, Mexico, Bulgar... and more
Sunovion

Completed

Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects

Chronic Obstructive Pulmonary Disease

United States
AstraZeneca

Completed

Long-term Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-36)

Chronic Obstructive Pulmonary Disease

United States, Canada
Universidad Nacional de Colombia
University of Barcelona

Recruiting

Physical Exercise and Responses Measured by HIF-1 in COPD (ECOPDHIF-1)

Pulmonary Disease, Chronic Obstructive

Colombia
MedImmune LLC
AstraZeneca

Completed

An Observational Study to Assess RSV-associated Illness in Adults With COPD and/or CHF (CD-1089)

Respiratory Syncytial Virus, Chronic Obstructive Pulmonary Disease, Congestive Heart Failure

United States, Bulgaria, France, Russian Federation, Canada, Sweden, Germany, Italy, Czech Republic
Novartis Pharmaceuticals

Completed

Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD

Chronic Obstructive Pulmonary Disease (COPD)

Germany, Belgium, Poland, Romania, Croatia, Estonia, Netherlands, Slovakia, Latvia, Lithuania, United Kingdom, Argentina, Bulgaria, Serbia, Austria, Hungary, Spain, Greece, Canada, Denmark, Czechia
Pearl Therapeutics, Inc.

Completed

Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)

Chronic Obstructive Pulmonary Disease (COPD)

United States
Bellerophon Pulse Technologies

Completed

Two-Part Dose-Confirming Study of Pulsed Inhaled Nitric Oxide in Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD

Chronic Obstructive Pulmonary Disease | Pulmonary Hypertension

United States
AstraZeneca

Completed

European Non-interventional Study in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease (COPD)

Sweden, France, Italy, Spain, Turkey, United Kingdom, Germany, Denmark, Finland, Netherlands, Norway, Austria, Belgium, Portugal, Greece, Ireland, Switzerland
Novartis

Completed

Safety, Tolerability and Efficacy of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

COPD

United States, Argentina, Germany, Spain, Canada, India, Turkey, Sweden, Italy
Novartis Pharmaceuticals

Completed

QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations)

Chronic Obstructive Pulmonary Disease (COPD)

Germany, Colombia, India, Korea, Republic of, Poland, Romania, South Africa, Italy, Austria, Belgium, Croatia, Estonia, Hungary, Russian Federation, Taiwan, Turkey, Japan, Spain, Sweden, United Kingdom, China, Thailand, Canada, Hong Kong and more
AstraZeneca

Completed

Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35) (LAS-MD-35)

Chronic Obstructive Pulmonary Disease

United States, Canada
Sanofi
Regeneron Pharmaceuticals

Active, not recruiting

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation (NOTUS)

Chronic Obstructive Pulmonary Disease

Greece, Belgium, Spain, Argentina, Hungary, South Africa, United Kingdom, France, Latvia, Germany, Netherlands, Russian Federation, Ukraine, United States, Australia, Brazil, Bulgaria, Canada, Chile, Colombia, Czechia, Lithuania, Me... and more
AstraZeneca

Completed

Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)

Chronic Obstructive Pulmonary Disease | COPD

United States, Argentina, Canada, Colombia, Mexico, Peru
Sanofi
Regeneron Pharmaceuticals

Recruiting

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-1)

Chronic Obstructive Pulmonary Disease

Bulgaria, China, United States, Argentina, Chile, Czechia, Georgia, Greece, Hungary, India, Israel, Italy, Mexico, Poland, Romania, Russian Federation, Slovakia, Taiwan, Ukraine, United Kingdom, Mauritius
AstraZeneca

Completed

Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

United States
Sanofi
Regeneron Pharmaceuticals

Recruiting

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-2)

Chronic Obstructive Pulmonary Disease

Korea, Republic of, Turkey, United States, Chile, Czechia, Israel, Russian Federation, Argentina, Brazil, Bulgaria, Canada, Denmark, Estonia, France, Georgia, Germany, Hungary, India, Japan, Latvia, Lithuania, Mexico, Netherlands, Norway and more
Sunovion

Completed

Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease | Emphysema | Bronchitis

United States
Xiromed LLC
Laboratorios Liconsa; Exeltis

Completed

Bioequivalence Study of Tiotropium 18 μg Inhalation Powder, Hard Capsule With Spiriva®Handihaler® 18 μg Inhalation Powder, Hard Capsule in Patients With Chronic Obstructive Pulmonary Disease (COPD) (ARBORUS)

COPD

United States, India
AstraZeneca

Completed

Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States, Australia, Canada, New Zealand
Sunovion

Completed

Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD

Chronic Obstructive Pulmonary Disease | Emphysema | Chronic Bronchitis

United States
Merck Sharp & Dohme LLC

Recruiting

MK-5475-013 INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of MK-5475 (an Inhaled sGC Stimulator) in Adults With PH-COPD

Chronic Obstructive Pulmonary Disease | Pulmonary Hypertension

United States, Korea, Republic of, Australia, Germany, Spain, Italy, Switzerland, France, Argentina, Colombia, Israel, Austria, Mexico, United Kingdom, Belgium, Turkey, Peru, South Africa
United Therapeutics

Terminated

A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD) (PERFECT)

Chronic Obstructive Pulmonary Disease | Pulmonary Hypertension

United States, Israel, Argentina, Puerto Rico
AstraZeneca

Completed

Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States, Australia, Canada, New Zealand
Verona Pharma plc
Iqvia Pty Ltd

Completed

A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD

Chronic Obstructive Pulmonary Disease

Korea, Republic of, United States, Bulgaria, Czechia, Germany, Greece, Hungary, Poland, Romania, Russian Federation, Slovakia, United Kingdom
Sanofi
Regeneron Pharmaceuticals

Completed

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation (BOREAS)

Chronic Obstructive Pulmonary Disease

Spain, Argentina, China, Mexico, Canada, Ukraine, Israel, Italy, Czechia, Korea, Republic of, Bulgaria, Chile, Denmark, Finland, Germany, Hungary, Japan, Poland, Romania, Russian Federation, Slovakia, Sweden, Turkey, United States
Sunovion

Completed

Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease | Emphysema | Bronchitis

United States
Novartis Pharmaceuticals

Completed

Exacerbation Study (INVIGORATE)

Chronic Obstructive Pulmonary Disease

Germany, Belgium, Colombia, Romania, South Africa, Italy, Hungary, Taiwan, Turkey, Switzerland, Australia, France, Israel, Sweden, China, Thailand, Estonia, Netherlands, Russian Federation, Slovakia, Spain, Argentina, Lithuania, Austria, Cana... and more
AstraZeneca

Completed

A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD

Chronic Obstructive Pulmonary Disease

United States, Peru, South Africa, Argentina, Mexico, Brazil, Chile, Colombia, Venezuela
University of British Columbia

Withdrawn

Does Pulmonary Rehabilitation Improve Breathing of COPD Patients (PR-COPD)

Pulmonary Disease, Chronic Obstructive

Canada

Clinical Trials on Chronic Obstructive Pulmonary Disease Severe in Colombia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Myanmar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations